200 related articles for article (PubMed ID: 24849527)
1. A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions.
Steinmetz T; Kindler M; Lange O; Vehling-Kaiser U; Kuhn A; Hellebrand E
Curr Med Res Opin; 2014 Sep; 30(9):1813-20. PubMed ID: 24849527
[TBL] [Abstract][Full Text] [Related]
2. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.
Pirker R; Hedenus M; Vansteenkiste J; Hernandez E; Belton L; Terwey JH
Clin Ther; 2016 Jan; 38(1):122-135.e6. PubMed ID: 26730453
[TBL] [Abstract][Full Text] [Related]
4. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
Mel JR; Salar A; Rodríguez CA; Alegre A; González A; Cassinello J; Montesinos J; Gasquet JA; Sánchez J; Saigí E;
Curr Med Res Opin; 2008 Oct; 24(10):2931-42. PubMed ID: 18775103
[TBL] [Abstract][Full Text] [Related]
5. A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice.
Van Belle S; Swieboda-Sadlej A; Karanikiotis C; Labourey JL; Galid A; Wheeler T; Pujol B; Aerts JG
Curr Med Res Opin; 2012 Jul; 28(7):1079-87. PubMed ID: 22642867
[TBL] [Abstract][Full Text] [Related]
6. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
Hudis CA; Vogel CL; Gralow JR; Williams D;
Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
[TBL] [Abstract][Full Text] [Related]
7. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
[TBL] [Abstract][Full Text] [Related]
8. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.
Aerts JG; Swieboda-Sadlej A; Karanikiotis C; Labourey JL; Galid A; Wheeler T; Pujol B; Van Belle S
Curr Med Res Opin; 2012 Jul; 28(7):1089-99. PubMed ID: 22642866
[TBL] [Abstract][Full Text] [Related]
9. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy.
Esquerdo G; Doménech M; López P; Pedro C; Villadiego K; Constenla M; Sánchez-Rovira P; Gasquet JA; Rodríguez CA;
Tumori; 2014; 100(2):225-31. PubMed ID: 24852870
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
11. A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia.
Ray-Coquard I; Laplaige P; Vey N; Asselain B; Urbieta M
Curr Med Res Opin; 2010 Nov; 26(11):2653-60. PubMed ID: 20932223
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia.
Boccia RV; Henry DH; Belton L; Bohac C; Ghazal HH
Cancer Med; 2016 Dec; 5(12):3445-3453. PubMed ID: 27882724
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
Bustos A; Álvarez R; Aramburo PM; Carabantes F; Díaz N; Florián J; Lázaro M; de Segovia JM; Gasquet JA; Alegre A;
Curr Med Res Opin; 2012 Jan; 28(1):57-67. PubMed ID: 22070513
[TBL] [Abstract][Full Text] [Related]
14. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.
Esquerdo G; Llorca C; Cervera JM; Orts D; Juárez A; Carrato A
Clin Transl Oncol; 2011 May; 13(5):341-7. PubMed ID: 21596663
[TBL] [Abstract][Full Text] [Related]
16. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
17. Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels.
Hess G; Hill J; Clough J; Hulnick S; Nordyke RJ
Curr Med Res Opin; 2008 Mar; 24(3):815-9. PubMed ID: 18257979
[TBL] [Abstract][Full Text] [Related]
18. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
Canon JL; Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Legg J; Pujol B; Bridges K
Med Oncol; 2012 Sep; 29(3):2291-9. PubMed ID: 22081263
[TBL] [Abstract][Full Text] [Related]
19. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
[TBL] [Abstract][Full Text] [Related]
20. Darbepoetin alpha as treatment for anemia in patients receiving chemotherapy: a single-center experience.
Bartsch R; Wenzel C; Sevelda U; Hussian D; Pluschnig U; Locker GJ; Mader R; Zielinski CC; Steger GG
Anticancer Drugs; 2005 Jul; 16(6):617-20. PubMed ID: 15930888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
